En Carta Diagnostics funding news – Deeptech Startup En Carta Diagnostics Secures €1.5 Million in Pre-Seed Funding

En Carta will be able to significantly advance its efforts to obtain preclinical data on a prototype diagnostic tool for its flagship indication, the debilitating Lyme disease, as a result of this investment, while also guaranteeing its industrial scalability.

The round was led by CentraleSupélec Venture, with a small number of prominent business entrepreneurs participating. To finance other diagnostic platform derivatives, additional funding may be imminent.

Read also - KARRI funding news – London-based KARRI Raises £775k in Pre-Seed Funding

En Carta's technology is a rapid Point-of-Care diagnostic platform that is characterised by high precision and is available in a parsimonious cassette format. This technology is the result of over ten years of intensive research.

It employs aptamers, which are capable of binding to a predetermined target with high affinity and specificity. An extensive array of applications is made possible by the ability to programme this "signature" to detect any genetic, pathogenic, or veterinary indication.

Guillaume Horreard, CEO at En Carta said, “En Carta is absolutely thrilled to have secured financial backing from CentraleSupélec Venture and business angels, who have deep expertise in healthcare and a solid understanding of Point-of-Care market needs, Today, we have a very robust platform technology leveraged for accuracy, speed and cost, which are key in the Point-of-Care space. As a first step, we are focusing on Lyme disease, where the sizeable patient population, accelerated growth of the problem and need for rapid diagnosis following a tick bite make our product indispensable.”

The proceeds will be utilised by En Carta to create a diagnostic device that is capable of independently detecting Lyme disease within minutes. Additionally, the funding will facilitate the development of a robust ecosystem and the execution of its go-to-market strategy.

Cédric Curtil, executive director of CS Venture said, “CentraleSupélec Venture is delighted to support this first phase of development in the Point-of-Care diagnostics sector, which meets the expectations of both patients and healthcare systems,”

The standard testing for Lyme disease has been deficient in the long-awaited early diagnosis of the disease, a critical capability that the platform enables. The current Lyme disease assays are intended to identify antibodies that the body produces in response to infection.

Tests conducted on patients who have been recently infected may yield a negative result, as antibodies can develop over a period of several weeks. En Carta's molecular diagnostic platform is the first to address this deficiency, thereby enabling more precise and rapid diagnosis. Preclinical data is anticipated to be presented by the organisation in the early months of 2025.

Jean-Pierre Millon, board member of CVS Health and advisor to En Carta. said, “En Carta Diagnostics’ technology, product and team are very promising. Their go-to-market approach for POC diagnostics could fulfill an unmet need in the US retail environment, as practitioners struggle with early diagnosis of Lyme Disease and co-infections,”

About En Carta Diagnostics

Diagnostics that enhance patient care, regardless of location. En Carta Diagnostics is a synthetic-biology biotech company that employs patented technologies to decentralise highly dependable molecular diagnostic solutions.